# Egbert F. Smit

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/egbert-f-smit/

## Facts

| Field | Value |
| --- | --- |
| Citations | 60,931 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 114 |
| i10-index | 510 |
| Last Known Institution | Leiden University Medical Center |
| OpenAlex ID | https://openalex.org/A5016904876 |
| ORCID iD | https://orcid.org/0000-0002-7329-6995 |
| Works | 1,209 |

## Researcher papers

Showing 12 of 13.

- [Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/metastatic-non-small-cell-lung-cancer-esmo-clinical-practice-guidelines-for-2/)
- [Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer](https://scholariq.org/papers/integrative-genome-analyses-identify-key-somatic-driver-mutations-of-small-cell/)
- [Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial](https://scholariq.org/papers/dabrafenib-plus-trametinib-in-patients-with-previously-untreated-brafv600e/)
- [Trastuzumab Deruxtecan in <i>HER2</i> -Mutant Non–Small-Cell Lung Cancer](https://scholariq.org/papers/trastuzumab-deruxtecan-in-i-her2-i-mutant-non-small-cell-lung-cancer/)
- [Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer](https://scholariq.org/papers/capmatinib-in-i-met-i-exon-14-mutated-or-i-met-i-amplified-non-small-cell-lung/)
- [Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations](https://scholariq.org/papers/tepotinib-in-non-small-cell-lung-cancer-with-i-met-i-exon-14-skipping-mutations/)
- [Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial](https://scholariq.org/papers/brigatinib-in-patients-with-crizotinib-refractory-anaplastic-lymphoma-kinase/)
- [2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up](https://scholariq.org/papers/2nd-esmo-consensus-conference-on-lung-cancer-early-stage-non-small-cell-lung/)
- [Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial](https://scholariq.org/papers/dabrafenib-in-patients-with-brafv600e-positive-advanced-non-small-cell-lung/)
- [A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)](https://scholariq.org/papers/a-randomized-phase-ii-study-of-the-mek1-mek2-inhibitor-trametinib-gsk1120212/)
- [Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer](https://scholariq.org/papers/second-esmo-consensus-conference-on-lung-cancer-pathology-and-molecular/)
- [HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy](https://scholariq.org/papers/herthena-lung01-a-phase-ii-trial-of-patritumab-deruxtecan-her3-dxd-in-epidermal/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Radiomics and Machine Learning in Medical Imaging](https://scholariq.org/topics/radiomics-and-machine-learning-in-medical-imaging/)

## Researcher university

- [Leiden University Medical Center](https://scholariq.org/institutions/leiden-university-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.